# Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis

> **NCT06723548** · PHASE4 · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Wenzhou Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Myasthenia Gravis
- Autoimmune Diseases

## Interventions

- **DRUG:** Telitacicept

## Key facts

- **NCT ID:** NCT06723548
- **Lead sponsor:** First Affiliated Hospital of Wenzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06723548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06723548, "Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06723548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*